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Abstract The mammalian brain is extremely sensitive to
alterations in cellular homeostasis as a result of environ-
mental or physiological insults. In particular, hypoxic/
ischemic challenges (i.e. reduced oxygen and/or glucose
delivery) cause severe and detrimental alterations in brain
function and can trigger neuronal cell death within minutes.
Unfortunately, as we age, oxygen delivery to cells and
tissues is impaired, thereby increasing the susceptibility of
neurons to damage. Thus, hypoxic (neuronal) adaptation is
significantly compromised during aging. Many neurological
diseases, such as stroke, Alzheimer’s disease (AD), Par-
kinson’s disease and diabetes, are characterized by hypoxia,
a state that is believed to only exacerbate disease progres-
sion. However, the contribution of hypoxia and hypoxia-
mediated pathways to neurodegeneration remains unclear.
This review discusses current evidence on the contribution
of oxygen deprivation to AD, with an emphasis on hypoxia
inducible transcription factor-1 (HIF-1)-mediated pathways
and the association of AD with the cytoskeleton regulator
cyclin-dependent kinase 5. (Part of a multi-author review.)
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Introduction
Proper neuronal activity is critical for the regulation of
physiological functions throughout the entire organism,
and any disruption of neuronal function has potentially
devastating consequences. Neurons are extremely depen-
dent on oxygen availability and demonstrate a high
vulnerability during conditions that cause or result in
alterations in oxygen supply. Even just a few minutes of
oxygen deprivation initiates significant dysfunction, and
longer episodes can ultimately result in the induction of
cell death [1].
Unfortunately, as we age, oxygen delivery to cells and
tissues is somewhat impaired, thereby increasing the sus-
ceptibility of neurons to damage. In addition, cellular
adaptation to hypoxia is significantly compromised with
increasing age and, at the same time, an ischemic episode
has a more dramatic outcome in old versus young patients
[2, 3]. In line with these findings, the risk of stroke doubles
with each decade after the age of 55 years, while two-thirds
of cerebral infarctions are reported in people over the age
of 65 [4]. Increased neuronal vulnerability is also very
evident in the sharp rise in the incidence of neurodegen-
erative diseases that occur in the later stages of life and as
the lifespan continues to increase. Indeed, mortality as a
result of neurological disorders constitutes 12% of total
deaths globally, while nervous system diseases lead to
more hospitalizations than any other disease group,
including heart disease and cancer, resulting in a burden on
both social and economic sectors of society.
A key characteristic of many neurodegenerative disorders
such as Alzheimer’s disease (AD), Parkinson’s disease and
frontotemporal dementias, is the accumulation of poten-
tially toxic proteins which although present throughout
life become neurotoxic as a result of environmental
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stimuli, including head injury, oxygen deprivation and oxi-
dative stress. The precise contribution of such stimuli to
neurodegeneration remains largely unknown, but reduced
oxygen supply seems to play a key role in being a cause and/
or consequence of neurodegeneration during the aging
process.
This review discusses current evidence on the contri-
bution of oxygen deprivation and HIF-1-mediated
pathways to neurodegeneration, with particular emphasis
on AD and the cytoskeleton regulator cyclin-dependent
kinase 5 (Cdk5).
Alzheimer’s pathogenesis
Alzheimer’s disease is a complex, progressive neurode-
generative disorder. Individuals affected with this disease
show severe memory and cognitive function impairment,
which is believed to be the outcome of disrupted neuronal
circuits and severe neuronal loss. The prevalence of AD is
directly related to age [5, 6] and represents an enormous
healthcare burden for society. Alzheimer’s disease is a
growing social and economic burden on the developed
world, with the current cost of care for patients with AD
around the world estimated at approximately $150 billion
annually.
The major pathological hallmarks of AD are large
extracellular b-amyloid (Ab) plaques and intraneuronal
neurofibrillary tangles (NFTs) composed of abnormally
hyperphosphorylated forms of the microtubule-associated
protein tau. Ab is the cleaved product of the transmem-
brane amyloid precursor protein (APP). The cleavage of
APP by b-secretase (b-site amyloid precursor protein
cleavage enzyme, BACE) and subsequently by the
c-secretase complex results in the formation of two Ab
isoforms, Ab40 and Ab42, that have neurotoxic potential.
Interestingly, the presence of Ab in the cerebrospinal fluid
(CSF) of healthy individuals and also in the media of
neuronal cultures suggests an additional physiological role
for Ab. Currently available evidence indicates that during
the initial phase of AD, both Ab deposition and the for-
mation of NFTs are the consequence of oxidative stress and
help to protect neurons against injury [7, 8].
However, during disease progression it appears that this
anti-oxidant capacity becomes pro-oxidant, promoting the
generation of free radicals, the disruption of microtubule
networks, disturbances in axoplasmic transport, synapse
loss and, eventually, neuronal death. It is therefore argued
that Ab becomes toxic only when the balance between its
production and degradation is disturbed as a result of
stressful stimuli. The density of NFTs correlates with the
severity of the AD symptoms, and a number of proteins,
such as protein kinases Cdk5 and glycogen synthase kinase
3 (GSK3), have been shown to be involved in tau hyper-
phosphorylation [9, 10].
Alterations in the actin cytoskeleton frequently accom-
pany AD pathology. Actin-rich inclusions, known as
Hirano bodies, as well as cofilin–actin rods have been
described in a number of neurodegenerative disorders
[11, 12]. Immunohistochemical studies have revealed that
Hirano bodies are mainly composed of actin microfila-
ments, although tau, tubulin and APP are also present [13].
The number of Hirano bodies increases during physiolog-
ical aging and is further increased in AD patients,
indicating their participation in disease pathogenesis [14].
Cofilin–actin rods, much smaller aggregates that appear as
separate units in AD brains, are also thought to give rise to
Hirano bodies over time [15].
Along with progressive Ab and NFT accumulation,
cytoskeletal and synapse disruption, AD pathology is fur-
ther characterized by inflammation as well as deficits in the
expression of neurotrophic factors, transcription factors
and antioxidant enzymes. Altogether these multi-faceted
events render the disease complex and thus particularly
difficult to treat.
Hypoxia and AD pathogenesis
Alzheimer’s disease is a multifactorial disease in which
both genetic and environmental factors contribute to—and
accelerate—disease progression. It is now apparent that
genetic predisposition is accountable for only a small
number of AD cases. Fully penetrant mutations leading to
protein cleavage and consequent aggregation are respon-
sible for only 5% of all AD cases and result in familial
early onset AD (from 65 years) [16]. Although most cases
have no known genetic basis, exposure to other pathogenic
conditions, including chronic inflammation, traumatic
brain injury, cerebrovascular disease, hypoxia/ischemia
and exposure to pesticides [5, 16–18], could be contribut-
ing factors.
It has been shown that individuals who have suffered
severe hypoxia or ischemia are more susceptible to
developing AD [19, 20]. The risk of incident dementia is
particularly elevated in association with illnesses that may
cause cerebral hypoxia or ischemia, suggesting that cere-
bral hypoperfusion may serve as a basis for some cases of
dementia after stroke [20]. Head injury also induces
ischemic changes that induce a tau-like pathology sub-
sequent to neuronal damage, indicating that such injuries/
insults can lead to a relatively rapid induction of APP and
amyloidogenic phenotypes even in the young brain [21]. In
vitro, when cortical neurons are treated with Ab concom-
itantly with hypoxic exposure, the number of apoptotic
neurons increase dramatically compared to treatment with
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Ab alone [22], indicating that hypoxia itself accelerates the
neuronal death observed in AD brains. Furthermore,
hypoxia has been found not only to contribute to plaque
formation in an AD transgenic mouse model but also to
increase the memory deficit characterizing these mice [23].
Thus, impairment of the proper oxygen supply has been
shown to be involved in AD pathogenesis, thereby sub-
stantiating clinical observations that associate hypoxic
episodes to AD.
Despite available evidence, the molecular mechanisms
that link hypoxia to AD pathogenesis are not well defined.
Hypoxia/ischemia upregulate APP at both the mRNA and
protein level and lead to subsequent Ab accumulation [19,
22, 24–27]. It is thought that an immediate increase in APP
levels is a defense mechanism employed to induce the
production of the cleaved soluble product APPa, which has
known neuroprotective properties [19]. Concomitantly,
however, these increased levels of APP provide the
resource for the generation and accumulation of Ab, which
also increases dramatically as a result of hypoxic injury.
Ab neurotoxic effects are also known to involve alterations
in Ca2? homeostasis, a key event in AD pathogenesis,
leading to cytoskeletal disruption and, eventually, neuronal
death [28, 29]. Prolonged hypoxia selectively upregulates
L-type Ca2? channels, an event that requires Ab formation,
since in its absence these channels are no longer affected
by the hypoxic insult [30]. Ab clearly interacts directly
with the a1 subunit, and hypoxia further promotes this
interaction, leading to an increased expression of functional
Ca2? channels at the cell membrane and thus an increase in
Ca2? influx [31], probably mediated by Ca2?-permeable
AMPA receptors [22]. This mechanism suggests that a
feedback loop between Ab and hypoxia may promote
disease progression. Other evidence shows that brief peri-
ods of hypoxia can potentiate the Ab-induced expression
of the pro-inflammatory markers cyclooxygenase-2 and
presenilin 1 (COX-2 and PS1, respectively), thus acceler-
ating the inflammatory neuropathology that characterizes
AD brains [32].
Taken together these data provide convincing evidence
that hypoxia contributes to AD pathogenesis through
amyloidogenesis and Ca2? dependent mechanisms. How-
ever, it is clear that many more studies are needed to fully
understand the impact of hypoxia-mediated changes on
neurodegenerative pathologies.
HIF-1 signaling during AD: a double-edged sword?
At the molecular level, a large percentage of hypoxic
responses are controlled by hypoxia-inducible transcription
factor-1 (HIF-1, reviewed by Webb et al. in this issue). The
HIF complex is a heterodimer composed of a constitutively
expressed HIF-1b subunit (also known as the aryl hydro-
carbon receptor nuclear translocation, ARNT) and a
HIF-1a oxygen-regulated subunit [33–37]. The regulation
of HIF-1a activity occurs at different levels, with such
processes as protein stability, phosphorylation and nuclear
translocation and activity, among others, all being influ-
enced by alterations in oxygen levels. HIF-1a is degraded
under normoxic conditions. In contrast, under hypoxic
conditions, HIF-1a is stabilized and translocated to the
nucleus where it dimerizes with ARNT and subsequently
binds to hypoxic binding sites (HBS) of target genes. The
HBS is a conserved consensus sequence (A/G)CGTG
within the hypoxic response element (HRE) present in
oxygen-regulated target genes involved in cell survival,
glycolysis, angiogenesis, erythropoiesis, and iron metabo-
lism [38]. The degradation of HIF-1a is triggered by the
oxygen-dependent hydroxylation of proline residues loca-
ted in the oxygen-dependent degradation domain mediated
by a family of prolyl hydroxylases, namely PHD1, PHD2,
and PHD3 [39–41]. These enzymes are specific HIF-1a
proline hydroxylases that require Fe(II) as a co-factor as
well as oxygen and 2-oxoglutarate as co-substrates [42,
43]. Prolyl hydroxylation promotes the recruitment of the
tumor suppressor protein von Hippel–Lindau, which is part
of the E3 ligase ubiquitination complex and primes HIF-1a
for degradation in the proteosomes.
Since hypoxia may mediate AD progression, is there
evidence to suggest that HIF-1 has a role in AD pathology?
It was apparent over a decade ago that the iron chelator
desferoxamine, which also induces and stabilizes HIF-1
expression, protects cultured cells from Ab [44] and
inhibits AD progression in patients [45]. A second metal
chelator, clioquinol, was subsequently shown to reverse
AD-like pathologies in transgenic mice [45] and induce
HIF-1 expression [35]. These studies provided the first
clues to the possible involvement of HIF-1 in neuro-
degenerative disorders, which is now becoming more
widely accepted. However, the precise role of the pathway,
albeit positive or negative, remains a matter of debate.
Notably, HIF-1-mediated signaling has been implicated
in both cell survival and cell death pathways [46], and the
modulation of the HIF pathway seems to be very complex.
During aging, the HIF induction and signaling pathways
are down-regulated [47]. This impairment of important
HIF-1 signaling pathways in the aged brain may render the
individual more susceptible to neurodegeneration. Soucek
et al. [35] showed that Ab directly induces HIF-1a
expression and activity in vitro. Interestingly, low levels
of Ab protect neurons from a more aggressive insult via
the induction of HIF-1a pathways and, crucially, over-
expression of HIF-1a has been found to be sufficient to
protect neurons from Ab neurotoxicity. A very recent study
also demonstrated that HIF-1 levels are further reduced in
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AD brains in comparison to age-matched controls [48],
again pointing to the possibly detrimental downregulation
of important HIF target genes. In line with this, the
observed decreased expression of two major brain glucose
transporters, GLUT1 and GLUT3, in the AD brain was
most probably the result of reduced levels of HIF-1, their
main regulator. The decrease in GLUT1 and GLUT3 levels
is also negatively correlated with tau hyperphosphorylation
and with an increased density of NFTs, providing evidence
for the involvement of glucose transporters in abnormal tau
hyperphosphorylation and the formation of NFTs, both
events being tightly linked to neurodegeneration [48].
Providing further support for the idea of a detrimental
down-regulation of HIF-1 target genes during disease,
Chong et al. [49] demonstrated a neuroprotective role
of erythropoietin (EPO), a well-described HIF-1 target,
against Ab toxicity in hippocampal neurons in vitro. In this
study, EPO was both necessary and sufficient to prevent
Ab-induced apoptotic death in both the early and later
stages of neurodegeneration via the expression and trans-
location of NF-kB p65. Similarly, levels of EPO in the CSF
of AD patients have been found to be reduced, or in the
same range, as those in control brains [50], a surprising
finding in light of upregulation of EPO in adults with
traumatic brain injury or depression. This once more
indicates that a deficiency of protective endogenous EPO in
dementia, again presumably due to decreased HIF
expression, may contribute to disease progression.
The lack of, or insufficient neuroprotective effects of
vascular endothelial growth factor (VEGF), another infa-
mous HIF target gene, has also been proposed to accelerate
neurodegenerative disorders [51]. The treatment of motor
neuron degeneration by intracerebroventricular delivery of
VEGF in a rat model of amyotrophic lateral sclerosis had
therapeutic effects [52], hinting perhaps that VEGF may
have an analogous role in AD. Polymorphisms in the pro-
moter region of VEGF were also suggested to be associated
with an increased risk of developing AD [53], although this
finding was not confirmed in subsequent studies [54, 55].
Notably, the precise contribution of this important growth
factor to AD progression remains as yet elusive.
Overall, it is perhaps not so surprising that, as a result of
the above studies, some scientists have proposed hypoxic
preconditioning as an alternative therapy to prevent the
deterioration of neuronal cells in AD [56]. However, since
contradictory results have also been published (reviewed
below) and it has also been shown that the manipulation of
hypoxic pathways can have many different outcomes,
much more evidence is needed to provide sufficient back-
ing to such potential therapies.
In complete contrast to the aforementioned data, con-
flicting evidence suggests that the induction of HIF
pathways as a consequence of AD could be detrimental to
neuronal survival by inducing apoptotic genes and pro-
inflammatory proteins. Recent evidence has shown a defi-
nite link between ischemia/hypoxia, HIF-1 and APP
processing/Ab production. Notably, Zhang et al. [57]
showed that during acute hypoxia, HIF-1 binding to the
BACE1 promoter induced BACE1 expression and resulted
in increased Ab production in neuroblastoma cells. More-
over, HIF-1a deficiency reduced BACE1 expression in the
cortex and hippocampus of transgenic mice, pointing to
HIF-1 as the primary mediator of the hypoxic induction of
BACE1. Wang et al. [58] showed that APH-1A expression
and subsequent c-secretase-mediated Ab and Notch gen-
eration are also regulated by HIF-1 binding to the APH-1A
promoter during hypoxia. Since inhibiting or reducing the
levels of secretase activity decreases the production of Ab
in the absence of severe detrimental phenotypes [59, 60], it
could be speculated that HIF-1 inhibition may provide an
alternative approach for therapeutic targeting.
This is further substantiated by the fact that brief periods
of hypoxia, which can potentiate the Ab-induced neural
expression of the pro-inflammatory markers COX-2 and
PS1 and accelerate the inflammatory neuropathology that
characterizes AD brains, most probably also occurs
throughout HIF signaling pathways [32]. In addition,
potential HIF binding sites identified on presenilin pro-
moter regions further imply that HIF-1 may be involved in
stress-mediated PS1 transcriptional regulation [61]. Thus,
episodic hypoxia during aging may drive the expression of
COX-2, PS1 and related genes by way of HIF-1 signaling
that ultimately contributes, cumulatively, to inflammatory
responses and amyloidogenic neuropathology.
Another AD event linked to HIF-1 is the oxidative
stress-induced accumulation of Ab and subsequent acti-
vation of the pro-death gene BNIP3 in primary cortical
neurons [62]. The knockdown of HIF-1a by RNA inter-
ference not only inhibits BNIP3 induction but also reduces
Ab-induced neuronal death. Thus, HIF-1 seems to mediate
a potentially pathological role of BNIP3 in AD etiology.
That hypoxia/HIF-1 signaling is involved in amyloidogenic
processing of APP and subsequent downstream events also
provides a good rationale for the increased incidence of AD
and neurodegeneration after cerebral ischemia and stroke.
However, despite this body of data suggesting that HIF-1
inhibition may also be a good therapeutic strategy, more
evidence is needed to understand whether the role of HIF-1
in neurodegeneration, especially in vivo, is beneficial or
detrimental.
Thus, the overall contribution of HIF signaling pathways
per se to the progression of neurodegenerative disease is still
very hazy. On the one hand, it would appear that aged
neurons with attenuated HIF signaling neuroprotective
pathways are more susceptible to neurodegeneration. On the
other hand, sustained activation of HIF also seems to be
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harmful and can accentuate undesirable disease character-
istics. Based on current research, it seems likely that the role
of HIF in neurodegeneration may greatly depend on whether
it is the cause or the consequence of disease progression.
Oxygen deprivation-mediated cytoskeletal alterations
and AD
Uncertainty still surrounds the sequence of events that lead
to AD pathogenesis. Nevertheless, cytoskeletal abnormal-
ities in postmortem AD brains, ranging from the formation
of NFTs to axonal and dendritic atrophy, and the deregu-
lation of cytoskeletal–regulatory proteins suggest that the
cytoskeleton is an important player in the disease. Altera-
tions in the actin cytoskeleton have been linked with both
hypoxic injury and neurodegeneration [63]. In neurons, the
dynamic regulation of actin microfilament polymerization
is implicated in maintaining dendritic structure and, nota-
bly, the number of dendritic spines is significantly
decreased in Alzheimer’s neurons, indicating that actin
plays an active role in disease progression [64]. Similarly,
oxygen deprivation in the brain also causes neurons to
undergo morphological changes, including process retrac-
tion and a loss of shape, which are partially attributable to
the depolymerization of actin filaments [65]. Hypoxia
causes decreased neuritic sprouting, impaired mitochon-
drial function, reduced expression of the proteins required
to maintain synaptic connections and, ultimately, neuronal
death [66]. Thus, similar cytoskeletal abnormalities typify
both oxygen-deprived and AD neurons.
Cofilins are actin-binding proteins regulating the assem-
bly and disassembly of actin filaments [67]. Following a
stressful stimulus, cofilins undergo changes in phosphory-
lation, leading to the formation of rod-shaped actin bundles,
commonly known as rods, which contribute to AD patho-
genesis by inhibiting vesicle transport and disrupting
synaptic function [15]. Interestingly, rods are also rapidly
formed in response to anoxia [68], indicating that alterations
in oxygen levels may be one underlying event contributing to
the synaptic deficits responsible for memory impairment in
AD patients. Independent studies have further documented a
direct effect of oxygen deprivation on neurofilament break-
down and tau hyperphophosphorylation both in vivo and in
vitro [69, 70]. Notably, cytoskeletal alterations are also
documented in a number of other (neuro)pathogenic diseases
and disorders characterized by oxygen deprivation [71].
Cdk5, hypoxic signaling and HIF-1
Neurofilaments (NFs) are cytoskeletal intermediate fila-
ments exclusively expressed in neurons that provide rigidity
and cell shape and facilitate intracellular transport and
guidance of axons and dendrites. An abnormal accumula-
tion of NFs is frequently detected in neurodegenerative
disorders, and this accumulation is considered to be a major
hallmark of neuronal dysfunction. NFTs are composed of
abnormally modified and hyperphosphorylated tau, NFs and
other cytoskeletal proteins. The cause of this aberrant
transformation is not fully understood, but it has been
attributed to perturbations in the normal balance of kinases
and phosphatases. In particular, the kinases GSK3 and
Cdk5, both of which have been co-purified with microtu-
bules, play significant roles in cytoskeletal protein
hyperphosphorylation and NFT generation [72, 73].
Cyclin-dependent kinase 5, a proline-directed serine/
threonine kinase, is an important regulator of the neuronal
cytoskeleton and yet another key player in neurodegener-
ation and AD pathogenesis [5]. Under normal conditions,
membrane-bound Cdk5 is critical for the maintenance of
neuronal survival. It exerts its function through the phos-
phorylation of a number of target proteins, including
cytoskeletal proteins, signal transduction kinases and
transcription factors [74]. Cdk5 is associated with two non-
cyclin activators, p35 and p39, both of which restrict Cdk5
activity to neurons, keep the protein attached to the
membrane and activate the protein via phosphorylation
[75]. However under pathological conditions, Cdk5 activity
is deregulated. First, an increase in Ca2? influx stimulates
the activation of calpains, a family of proteases with a key
role in maintaining the cytoskeletal architecture [76].
Calpain then cleaves p35 and p39, the main regulators of
Cdk5, resulting in the generation of truncated products, p25
and p29, respectively. This cleavage leads to loss of the
protein complex membrane attachment, mislocalization of
Cdk5 and deregulation of its activity [77]. The hyperacti-
vation of Cdk5 is tightly linked to the Alzheimer’s
pathogenesis observed in postmortem brains and in neurons
exhibiting NFT. Cdk5 has also been shown to physically
interact and phosphorylate tau in vivo [78, 79].
However, it appears that Cdk5 regulation is also com-
plex since some recent data have suggested that transient
upregulation of Cdk5 activity in the adult brain as a result
of DNA damage is beneficial and protects neurons from
death. Studies have shown that Cdk5 phosphorylates and
inhibits c-Jun N-terminal kinase, thereby countering the
induction of apoptotic signals [80]. Furthermore, O’Hare
et al. [81] showed that cytoplasmic Cdk5 is neuroprotective
in models of excitotoxicity and DNA damage in vitro,
whereas nuclear Cdk5 is harmful and contributes to neu-
ronal death. Thus, localization may also play a key role in
determining the pro-survival or pro-death functions of this
kinase. The molecular mechanisms that regulate the ben-
eficial versus detrimental effects of Cdk5 are still to be
determined.
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It is now apparent that Cdk5/p35 may be involved in the
regulation of oxidative stress-mediated pathways [82]. The
first evidence of a role for the Cdk5/p35 complex in neu-
ronal responses to oxygen deprivation came from research
on Drosophila almost a decade ago [83]. Since then, a
number of studies have reported upregulation of the com-
plex in models of ischemia both in vivo and in vitro [84–
87], additionally implicating modulation of this pathway
during ischemic injury. Interestingly, similar to HIF-1
regulation, oxidative stress induces the activity of Cdk5,
and overall expression is downregulated with age in the
human brain [88]. Tamada et al. [89] demonstrated that p35
is cleaved during hypoxia as a result of calpain activation
in mouse retina neurons. Vartianen et al. [90] also showed
that Cdk5 activity and p35 expression play an important
role in aspirin-induced tolerance in rat neurons against
hypoxia/reoxygenation damage.
Very recent results from our group show that oxygen
deprivation alone induces cytoskeletal rearrangement and
distinctly modulates both components of the complex
(Antoniou et al., unpublished data); these results are in
agreement with those of another study showing increased
activation of Cdk5 in neuroblastoma cells subjected to
chemical oxidative stress [87]. Thus, hypoxia and oxidative
stress both significantly alter Cdk5 activity, and this could
have important consequences for neuronal function and
survival since the localization of Cdk5 has been suggested
to determine neuronal fate [81]. In agreement with this
suggestion, hypoxia has been observed to cause the redis-
tribution of Cdk5 to mainly the neuronal soma, signifying
an altered function for the kinase and possible interaction
with aberrant proteins. The nuclear translocation of Cdk5
can modulate transcription factors that are involved in cell
death pathways [81] and, importantly, we have observed
that Cdk5 function can regulate the expression of HIF-1 in
primary cortical neurons during hypoxic exposure. Notably,
pharmacological inhibition of Cdk5 by roscovitine attenu-
ated HIF-1a induction in a time-dependent manner and
additionally induced dramatic downregulation of EPO
mRNA hypoxic induction in primary cortical neurons
(Antoniou et al., unpublished data). In contrast, the sur-
prising inability of roscovitine treatment to alter VEGF
mRNA induction suggests that Cdk5 differentially modu-
lates hypoxic-induced signaling pathways. This observation
could be of importance in terms of improving our under-
standing of the mechanisms of neuronal survival and the
progression of neurodegenerative disorders in general as
well as of treatment therapies as a whole. Roscovitine
treatment has been found to exacerbate cell death during
chronic hypoxia, suggesting the requirement of Cdk5
function in the modulation of neuronal survival pathways
during long-term injury/insult, presumably via the modu-
lation of HIF-1 signaling. As such, these pathways may be
intertwined with pathogenetic disease progression that
occurs over extended time periods. Unfortunately, the
mechanism of Cdk5-regulated HIF induction is still unclear,
and how specificity for target gene induction is determined
remains perplexing. These and other important questions
are now being fully addressed in our ongoing studies.
Nevertheless, our current evidence supports the notion that
Cdk5, a regulator of AD pathogenesis, does play a benefi-
cial role during hypoxic events and interacts with HIF-1 to
modulate neuronal fate during neurodegenerative-related
processes. Taken together, these findings underline the
importance of obtaining a better understanding of the
overlap and contribution of HIF-1 pathways to AD.
Summary
It is blatantly clear that the increasing incidence of neuro-
degenerative diseases is a growing problem in all the
world’s societies. Although the precise mechanisms of age-
dependent neuronal susceptibility are unknown, a decreased
expression of cellular defense genes in the aged brain make
the latter less able to withstand injury. The current chal-
lenge is to find ways to increase the adaptive reserve of the
organism to combat such age-related deficits and support or
promote normal neuronal function. Oxygen deprivation
seems to characterize most pathological processes and
diseases, and in this regard neurodegeneration is no
exception. How oxygen deprivation affects the progression
of such disorders remains unclear, but it seems likely that it
can only serve to exhaust the adaptive reserves of the brain.
Thus, it is more and more crucial to explore the contribution
of hypoxic-mediated pathways to age-related pathogenesis
in order to gain more knowledge on how to intervene during
disease progression. In the future, it may be that the
manipulation of hypoxia and/or HIF-modulated signaling
will provide new hope for the development of novel ther-
apies urgently needed to combat neurodegenerative disease.
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